Thymosin Alpha-1
Also known as: Tα1, TA1, Thymalfasin, Zadaxin
Thymosin Alpha-1 is a peptide originally isolated from thymic tissue that modulates immune function. It is approved in several countries for immune deficiency conditions and as an adjuvant therapy.
Key Findings at a Glance
- • Thymosin Alpha-1 is approved in over 35 countries for treating hepatitis B and C and as an immune enhancer, giving it one of the broadest regulatory footprints of any peptide worldwide.
- • Thymosin Alpha-1 enhances vaccine efficacy in immunocompromised populations including the elderly and HIV patients, where standard vaccines often produce inadequate immune responses.
- • Thymosin Alpha-1 simultaneously activates dendritic cells, natural killer cells, and both CD4+ and CD8+ T cells, orchestrating a coordinated immune response rather than boosting a single pathway.
- • Unlike most immunostimulants, Thymosin Alpha-1 also promotes immune tolerance through regulatory T cell induction, reducing the risk of autoimmune overactivation.
Thymosin Alpha-1 Overview & Molecular Profile
Thymosin Alpha-1 is a 28-amino-acid peptide first isolated from bovine thymus by Goldstein et al. in 1977. The synthetic version (Thymalfasin) is approved in over 35 countries for chronic hepatitis B/C, immunodeficiency states, and as a chemotherapy adjuvant. Key mechanisms include T-cell maturation, Th1 cytokine enhancement (IFN-γ and IL-2), and TLR-9 pathway activation in dendritic cells. It is not FDA-approved in the United States.
Mechanism of Action: Immunomodulation & Antimicrobial Activity
Thymosin Alpha-1 enhances immune function through multiple mechanisms. It promotes T-cell maturation and differentiation, enhances dendritic cell function, increases natural killer cell activity, and modulates cytokine production. It acts through Toll-like receptors and affects the balance between Th1 and Th2 immune responses.
Thymosin Alpha-1 Pharmacokinetics: Approved Immunomodulator Dosing Profile
Thymosin Alpha-1 has a plasma half-life of approximately 2 hours following subcutaneous injection at the approved dose of 1.6 mg, with complete bioavailability by the SC route. The twice-weekly dosing regimen used in clinical practice across 35+ countries reflects the fact that immunological effects persist far beyond the peptide's plasma presence, with Th1 cytokine elevation and T-cell activation peaking at 24-48 hours and lasting 5-7 days after a single dose.
Absorption and Distribution
- • Plasma half-life of approximately 2 hours after subcutaneous injection of 1.6 mg, with peak plasma concentration (Cmax ~20 ng/mL) reached within approximately 2 hours.
- • Complete bioavailability by the subcutaneous route — no first-pass metabolism reduces the administered dose.
- • The peptide is degraded by tissue peptidases; no significant renal excretion of intact peptide occurs, and no dose adjustment is required for hepatic or renal impairment.
- • The standard approved regimen of 1.6 mg SC twice weekly (e.g., Monday/Thursday) has been validated across multiple RCTs in chronic hepatitis B, hepatitis C, and cancer adjuvant settings.
Immune Response Kinetics
- • Immunological effects dramatically outlast the 2-hour plasma half-life: CD4+ T-cell activation, natural killer cell enhancement, and Th1 cytokine elevation (IFN-gamma, IL-2) peak at 24-48 hours post-injection and persist for 5-7 days.
- • This pharmacokinetic-pharmacodynamic disconnect explains why twice-weekly dosing — rather than daily — provides sustained immune enhancement, as each injection initiates a multi-day immunological cascade.
- • TLR-9 activation in dendritic cells triggers downstream signaling (MyD88-dependent pathway) that upregulates CD80, CD86, and MHC-II expression over days, amplifying antigen presentation capacity well after the peptide itself has been cleared.
- • Clinical approval in 35+ countries (as Thymalfasin/Zadaxin) with the 1.6 mg twice-weekly SC regimen provides extensive real-world pharmacokinetic validation across diverse patient populations including hepatitis, cancer, and immunodeficiency states.
Thymosin Alpha-1 Pharmacokinetics: Plasma Clearance vs Immune Effect Duration
Figure: Thymosin Alpha-1 plasma levels (blue) peak at ~2 hours and are cleared within 8-12 hours (t½ ~2h). Immunological effects (green dashed) — Th1 cytokine elevation, NK cell enhancement, T-cell activation — peak at 24-48 hours and persist for 5-7 days, explaining why twice-weekly dosing (approved in 35+ countries) maintains sustained immune enhancement.
Research-Observed Effects
T-Cell Modulation
Extensive ResearchThymosin Alpha-1 demonstrates profound effects on T lymphocyte maturation, differentiation, and functional activation, representing one of the most extensively studied peptide immunomodulators for adaptive immune system enhancement. Research shows the peptide promotes maturation of CD4+ helper T cells and CD8+ cytotoxic T cells from precursor thymocytes, with studies documenting increased T cell receptor diversity and improved antigen recognition capacity in treated subjects. Clinical trials have demonstrated 30-50% increases in peripheral T lymphocyte counts and enhanced lymphocyte proliferation responses to mitogenic stimulation following Thymosin Alpha-1 administration. The peptide modulates the Th1/Th2 balance by promoting interferon-gamma production and Th1 responses essential for antiviral and antitumor immunity, while maintaining appropriate regulatory T cell function to prevent autoimmune complications. Studies in immunocompromised patients including those with HIV/AIDS and post-chemotherapy immunosuppression show restoration of T cell numbers and function toward normal ranges. These T-cell modulation properties make Thymosin Alpha-1 essential for immunodeficiency research, viral hepatitis treatment investigations, and developing peptide-based immune reconstitution therapies for patients with compromised adaptive immunity.
Innate Immune Enhancement
Extensive ResearchResearch demonstrates Thymosin Alpha-1's significant enhancement of innate immune system function through activation of dendritic cells, macrophages, and natural killer cells that provide the first line of defense against pathogens and malignant cells. Studies show the peptide activates dendritic cells through Toll-like receptor (TLR) 2 and TLR9 signaling pathways, enhancing antigen presentation capacity and cytokine production for improved immune surveillance. Research documents increased natural killer cell cytotoxicity by 40-60% following Thymosin Alpha-1 treatment, with enhanced recognition and killing of virus-infected and tumor cells through granzyme and perforin-mediated mechanisms. The peptide promotes macrophage activation and polarization toward the M1 phenotype associated with enhanced microbicidal activity and pro-inflammatory cytokine production including IL-12 and TNF-alpha. Studies in neutropenic patients demonstrate improved neutrophil recovery and function, reducing infection risk during periods of vulnerability. These innate immune enhancement properties position Thymosin Alpha-1 as a critical research compound for immunotherapy development, cancer treatment adjuvant research, and understanding the interplay between innate and adaptive immunity in host defense mechanisms.
Viral Infection Research
Extensive ResearchExtensive clinical research in chronic hepatitis B and hepatitis C infections demonstrates Thymosin Alpha-1's immunomodulatory effects that support viral clearance and sustained virological response when used as monotherapy or in combination with standard antiviral treatments. Clinical trials have documented hepatitis B surface antigen (HBsAg) seroconversion rates of 25-40% with Thymosin Alpha-1 therapy, significantly higher than historical controls, with sustained responses maintained years after treatment completion. Studies in chronic hepatitis C show enhanced sustained virological response rates when Thymosin Alpha-1 is combined with interferon-alpha therapy, particularly in difficult-to-treat patient populations with high viral loads or previous treatment failures. Research indicates the peptide enhances antiviral immune responses by promoting cytotoxic T lymphocyte activity against virus-infected hepatocytes and increasing interferon-gamma production for direct antiviral effects. Emerging research explores Thymosin Alpha-1's potential for other viral infections including influenza, HIV as an adjunct therapy, and novel viral pathogens where immune enhancement may improve outcomes. These viral infection research applications have established Thymosin Alpha-1 as an approved therapeutic in over 35 countries for hepatitis treatment and continue to drive investigation into peptide-based antiviral immunotherapy approaches.
Vaccine Adjuvant Effects
Moderate ResearchResearch indicates Thymosin Alpha-1's significant potential to enhance vaccine efficacy through improved immune responses including increased antibody titers, enhanced T cell priming, and prolonged immunological memory formation. Studies demonstrate that co-administration of Thymosin Alpha-1 with influenza vaccines increases seroconversion rates by 20-30% compared to vaccine alone, particularly in elderly and immunocompromised populations where vaccine responses are typically suboptimal. Research shows the peptide enhances dendritic cell activation and antigen presentation, improving the initial immune recognition of vaccine antigens that drives subsequent adaptive immune responses. Clinical trials in cancer vaccine research demonstrate improved tumor-specific T cell responses and clinical outcomes when Thymosin Alpha-1 is used as an immunological adjuvant alongside tumor antigen vaccines. Studies in hepatitis B vaccination show accelerated seroprotection development and higher peak antibody titers in Thymosin Alpha-1 treated groups, suggesting applications for improving vaccination outcomes in non-responder populations. These vaccine adjuvant properties have significant implications for pandemic preparedness, cancer immunotherapy optimization, and developing improved vaccination strategies for vulnerable populations with impaired immune responses.
Cancer Immunotherapy Support
Moderate ResearchEmerging clinical research demonstrates Thymosin Alpha-1's potential as an adjunctive therapy in cancer treatment, enhancing tumor-specific immune responses and improving outcomes when combined with conventional therapies including chemotherapy, radiation, and targeted treatments. Studies in hepatocellular carcinoma patients show improved overall survival and disease-free survival rates when Thymosin Alpha-1 is added to standard treatment protocols, with research documenting enhanced tumor-infiltrating lymphocyte activity and reduced tumor recurrence. Research indicates the peptide helps restore immune function compromised by cancer-associated immunosuppression and treatment-related toxicity, maintaining effective anti-tumor immunity throughout therapy courses. Clinical trials demonstrate reduced chemotherapy-related immunosuppression and faster immune recovery following treatment cycles in patients receiving Thymosin Alpha-1 support, potentially allowing for more intensive treatment regimens. The peptide's ability to enhance natural killer cell cytotoxicity and cytotoxic T lymphocyte function provides mechanisms for improved tumor cell recognition and elimination. These cancer immunotherapy applications position Thymosin Alpha-1 as an important adjunctive agent in oncology research, particularly for tumors with immune evasion characteristics and in patients with compromised baseline immunity.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Thymosin Alpha-1 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 1.6 mg | 2× per week | Approved clinical dose for hepatitis B/C (Thymalfasin/Zadaxin) |
| Subcutaneous | 1.6–6.4 mg | Varies by protocol | Higher doses studied in cancer adjuvant and severe immunodeficiency contexts |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Thymosin alpha 1: a comprehensive review of the literature
Romani L, Bistoni F, et al.
Annals of the New York Academy of Sciences (2012)
This comprehensive review synthesizes over three decades of research on Thymosin Alpha-1, examining its immunomodulatory mechanisms, clinical applications, and therapeutic potential across diverse disease states including chronic infections, immunodeficiency, and cancer. The authors analyze molecular mechanisms including Toll-like receptor activation, cytokine modulation, and effects on both innate and adaptive immune cell populations that underlie the peptide's broad immunostimulatory profile. Extensive clinical trial data is presented demonstrating Thymosin Alpha-1's efficacy in chronic hepatitis B and C treatment, with detailed analysis of virological response rates, seroconversion percentages, and long-term follow-up outcomes across multiple international studies. The review examines the peptide's role in cancer immunotherapy as an adjunctive agent, documenting improved survival outcomes and reduced treatment-related immunosuppression in hepatocellular carcinoma and other malignancies. Safety data from thousands of treated patients confirms Thymosin Alpha-1's favorable tolerability profile with minimal adverse effects, supporting its use in vulnerable patient populations including the elderly and immunocompromised.
Thymosin alpha 1 enhances immune responses through activation of dendritic cells and Toll-like receptor signaling
Pica F, Gaziano R, et al.
Expert Opinion on Biological Therapy (2018)
This mechanistic study investigated the molecular pathways through which Thymosin Alpha-1 enhances immune function, specifically focusing on dendritic cell activation and Toll-like receptor signaling cascades critical for innate-adaptive immune crosstalk. Researchers demonstrated that Thymosin Alpha-1 activates dendritic cells through TLR2 and TLR9 engagement, triggering MyD88-dependent signaling cascades that promote cytokine production including IL-12, IFN-alpha, and TNF-alpha essential for antiviral and antitumor responses. The study documented enhanced dendritic cell maturation markers including CD80, CD86, and MHC class II expression following peptide treatment, indicating improved antigen presentation capacity for T cell priming. Functional assays showed Thymosin Alpha-1-treated dendritic cells induced stronger T cell proliferation and IFN-gamma production compared to untreated controls, confirming enhanced immunostimulatory capacity. These mechanistic insights established the scientific foundation for Thymosin Alpha-1's clinical applications in immune enhancement and informed development of combination immunotherapy strategies for chronic infections and cancer treatment.
Thymosin alpha 1 in the treatment of chronic hepatitis B: results from clinical trials
Chan HL, Tang JL, et al.
Alimentary Pharmacology & Therapeutics (2001)
This meta-analysis and clinical review examined the efficacy of Thymosin Alpha-1 for chronic hepatitis B treatment, pooling data from multiple randomized controlled trials to provide comprehensive assessment of virological and clinical outcomes. Analysis of combined trial data demonstrated significantly higher rates of HBeAg seroconversion (36% vs 19%) and HBV DNA clearance in Thymosin Alpha-1 treated patients compared to controls, with sustained responses maintained at long-term follow-up. The review documented that combination therapy with interferon-alpha produced additive or synergistic effects, with seroconversion rates approaching 45-50% in some combination arms. Safety analysis across trials confirmed excellent tolerability with adverse event rates similar to placebo, distinguishing Thymosin Alpha-1 from interferon therapy's significant side effect burden. These clinical findings established the evidence base for Thymosin Alpha-1's regulatory approval in multiple countries for hepatitis B treatment and continue to inform clinical practice guidelines for immune-based antiviral therapy approaches.
Comparative Research
Explore in-depth research analyses and comparative studies featuring Thymosin Alpha-1.
Comparative Clinical Analysis
Thymosin Alpha-1 vs LL-37: Immune-Modulating Peptide Comparison | Peptpedia
Thymosin Alpha-1 and LL-37 are two well-characterized immune-modulating peptides with complementary but distinct mechanisms. Thymosin Alpha-1 is a thymic hormone that primarily modulates adaptive immunity through T-cell maturation and Th1 cytokine enhancement, with regulatory approval in 35+ countries. LL-37 is an endogenous antimicrobial peptide from the cathelicidin family that bridges innate and adaptive immunity through direct microbial killing and immune cell signaling.
Epithalon vs Thymosin Alpha-1: Anti-Aging vs Immune Peptide Comparison | Peptpedia
Epithalon and Thymosin Alpha-1 represent distinct but complementary approaches to age-associated decline. Epithalon is a pineal tetrapeptide studied for telomere elongation and telomerase activation; Thymosin Alpha-1 is a thymic peptide with regulatory approvals for immune modulation. Both are extensively researched in the context of aging, but Thymosin Alpha-1 has substantially stronger clinical evidence.
Frequently Asked Questions
How does Thymosin Alpha-1 differ from Thymosin Beta-4?
Despite the similar name, these are completely distinct peptides. Thymosin Alpha-1 (28 amino acids) is a thymic hormone involved in T-cell maturation and immune activation—its primary applications are infectious disease and immune modulation. Thymosin Beta-4 (TB-500; 43 amino acids) is an actin-sequestering peptide primarily involved in cytoskeletal organization, cell migration, and tissue repair. They derive from different protein families, act through different receptors, and have non-overlapping research applications. TB-500 has no significant immunomodulatory actions; Thymosin Alpha-1 has no significant tissue repair actions.
In which countries is Thymosin Alpha-1 approved and for what?
Thymalfasin (synthetic Thymosin Alpha-1; brand name Zadaxin, manufactured by SciClone Pharmaceuticals) is approved in 35+ countries. In China—the largest market—it is approved for chronic hepatitis B, chronic hepatitis C, lung cancer adjuvant, and as a vaccine adjuvant in immunocompromised patients. In Italy it is approved for hepatitis B and as a chemotherapy immune adjuvant. It is not FDA-approved in the United States as of 2026, though clinical trials have been conducted. The clinical regulatory record is more extensive than virtually any other peptide in the research catalog.
What is the evidence for Thymosin Alpha-1 in chronic hepatitis B?
Meta-analysis of multiple RCTs shows that Thymosin Alpha-1 (1.6 mg SC twice weekly for 6–12 months) achieves HBeAg seroconversion in 36% of patients versus 19% in controls. Combination with interferon-alpha increases seroconversion to approximately 45–50%. The effect is mediated through restoration of Th1 cytokine responses (IFN-γ, IL-2) that are typically suppressed during chronic HBV infection. Compared to interferon monotherapy, Thymosin Alpha-1 has a markedly superior side effect profile, though it has been partially superseded by nucleoside analog antivirals (tenofovir, entecavir) in Western practice guidelines.
How was Thymosin Alpha-1 evaluated during COVID-19?
During COVID-19, several Chinese hospitals used Thymosin Alpha-1 as adjuvant therapy for severe COVID-19 based on its established immunomodulatory profile. A 2020 study in Clinical Infectious Diseases reported that Thymosin Alpha-1 treatment in severe COVID-19 patients reduced 28-day mortality from 30.9% to 19.3% (N=76 patients per arm). The proposed mechanism was restoration of CD4+ and CD8+ T-cell counts that are profoundly depleted in severe COVID-19, reversing lymphopenia. These are preliminary findings from a single-center study and require replication, but generated significant research interest in immunomodulatory peptides for viral hyperinflammation.
How does Thymosin Alpha-1 work through Toll-like receptors?
Thymosin Alpha-1 activates dendritic cells via TLR2 and TLR9 (Toll-like receptors 2 and 9) engagement. TLR9 normally recognizes bacterial and viral CpG-DNA motifs as 'danger signals.' TA1-induced TLR9 activation triggers MyD88-dependent signaling that produces IL-12, IFN-α, and TNF-α—cytokines essential for Th1 immune response initiation. The same signaling enhances dendritic cell maturation (upregulating CD80, CD86, and MHC-II), improving antigen presentation to naive T cells. This mechanism explains how Thymosin Alpha-1 can improve vaccine responses in immunocompromised patients—it enhances the adjuvant sensing pathways that drive adaptive immunity.
Has Thymosin Alpha-1 been studied for sepsis or critical illness?
Yes. Multiple Chinese RCTs administered Thymosin Alpha-1 to sepsis patients and found reduced 28-day mortality in immunoparalyzed patients (those with low HLA-DR expression on monocytes, indicating immune exhaustion). A landmark study (PMID: 21460542) showed that TA1 reduced mortality specifically in patients with sepsis-induced immunosuppression—those with the lowest immune function at baseline. A meta-analysis of 10 RCTs showed TA1 significantly reduced sepsis mortality (RR ~0.68) in Chinese clinical settings. The therapy is not standard of care in Western sepsis guidelines, but the evidence base is substantial relative to most peptides.
What is the role of Thymosin Alpha-1 in cancer immunotherapy?
Thymosin Alpha-1 has been studied as an adjuvant to cancer chemotherapy and immunotherapy, primarily to counteract therapy-induced lymphopenia and improve anti-tumor immune responses. Studies in lung and liver cancer showed that TA1 addition to chemotherapy regimens improved response rates by restoring CD4+ and CD8+ T-cell function depleted by cytotoxic agents. More recently, research has examined TA1 combinations with checkpoint inhibitors (PD-1/PD-L1 antibodies) to enhance T-cell tumor infiltration—an area of active investigation given the mechanistic overlap between T-cell checkpoint biology and thymic peptide immunomodulation.
What are the pharmacokinetics of Thymosin Alpha-1 (Zadaxin)?
Thymosin Alpha-1 administered subcutaneously at 1.6 mg reaches peak plasma concentration in approximately 2 hours (Cmax ~20 ng/mL), with a half-life of about 2 hours. It is completely bioavailable by the SC route. The peptide is degraded by tissue peptidases; no significant renal excretion of intact peptide occurs. Immunological effects (CD4+ T-cell activation, natural killer cell enhancement) persist well beyond the pharmacokinetic elimination window—effects peak at 24–48 hours post-injection and persist for 5–7 days, explaining why twice-weekly dosing provides sustained immune enhancement.
Related Peptides
View allLL-37
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in innate immunity. It has broad-spectrum antimicrobial activity and immunomodulatory properties.
TB-500
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a crucial role in tissue repair, cell migration, and blood vessel formation in the body.
Thymulin
Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells that plays a central role in T-cell differentiation, immune regulation, and the neuroendocrine-immune axis.
Related Comparisons
Thymosin Alpha-1 vs LL-37
Thymosin Alpha-1 and LL-37 are two well-characterized immune-modulating peptides with complementary but distinct mechanisms. Thymosin Alpha-1 is a thymic hormone that primarily modulates adaptive immunity through T-cell maturation and Th1 cytokine enhancement, with regulatory approval in 35+ countries. LL-37 is an endogenous antimicrobial peptide from the cathelicidin family that bridges innate and adaptive immunity through direct microbial killing and immune cell signaling.
Epithalon vs Thymosin Alpha-1
Epithalon and Thymosin Alpha-1 represent distinct but complementary approaches to age-associated decline. Epithalon is a pineal tetrapeptide studied for telomere elongation and telomerase activation; Thymosin Alpha-1 is a thymic peptide with regulatory approvals for immune modulation. Both are extensively researched in the context of aging, but Thymosin Alpha-1 has substantially stronger clinical evidence.